BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/2/2023 1:29:51 PM | Browse: 226 | Download: 541
 |
Received |
|
2022-11-23 10:55 |
|
Peer-Review Started |
|
2022-11-23 10:57 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-01-05 08:30 |
|
Revised |
|
2023-01-23 18:42 |
|
Second Decision |
|
2023-02-13 04:06 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2023-02-13 07:10 |
|
Articles in Press |
|
2023-02-13 07:10 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-02-21 05:44 |
|
Publish the Manuscript Online |
|
2023-03-02 13:29 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Hematology |
| Manuscript Type |
Minireviews |
| Article Title |
Immune-related adverse events induced by programmed death protein-1 inhibitors from the perspective of lymphoma immunotherapy
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yong-Zhe Hou, Qin Zhang, Hai Bai, Tao Wu and Ya-Jie Chen |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Gansu Province Innovation Base and Talent Plan (Gansu Province Leukemia Clinical Research Center) |
21JR7RA015 |
| Graduate Innovation Foundation of Major Project of Education Department of Gansu Province |
lccx2021001 |
| Gansu Provincial Science and Technology Plan Project Assignment (Innovation Base and Talent Plan) |
21JR7RA013 |
| 2022 Project of Innovation Foundation of Outstanding Graduate Students of Gansu Province |
|
| 2022 Hospital Project of The 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army |
2022yxky015 |
|
| Corresponding Author |
Hai Bai, Doctor, Research Scientist, Department of Hematology, Center of Hematologic Diseases of Chinese PLA, The 940th Hospital of Joint Logistics Support force of Chinese People's Liberation Army, No. 333 Nanbinhe Road, Qilihe District, Lanzhou 730050, Gansu Province, China. baihai98@tom.com |
| Key Words |
Lymphoma; Programmed cell death 1 receptor; Immune checkpoint inhibitors; Immune-related adverse events; Nivolumab; Pembrolizumab |
| Core Tip |
Much work on immune checkpoint immunotherapy as cancer therapy has been made in recent years. In lymphoma, the immune checkpoint pathway is used to evade the host immune system and suppress immune cell function. Use of programmed cell death 1 protein (PD-1) inhibitors in lymphoma is supported by their unprecedented clinical efficacy in a range of tumors. Lymphoma patients treated with PD-1 inhibitors inevitably experience immune-related adverse events (irAEs), ranging from mild to life-threatening. Although irAEs can be managed with therapy, severe irAEs may necessitate suspension or even interruption of patient-beneficial PD-1 antibody therapy. It is essential that clinicians take adequate care when irAEs occur. |
| Publish Date |
2023-03-02 13:29 |
| Citation |
Hou YZ, Zhang Q, Bai H, Wu T, Chen YJ. Immune-related adverse events induced by programmed death protein-1 inhibitors from the perspective of lymphoma immunotherapy. World J Clin Cases 2023; 11(7): 1458-1466 |
| URL |
https://www.wjgnet.com/2307-8960/full/v11/i7/1458.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v11.i7.1458 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
